Medicare Boosts, Billion-Dollar Buyouts, and Weight-Loss Pill Demand Propel Health Sector Buzz
Published on: April 7, 2026, 2:29 a.m. | Source: Devdiscourse
The U.S. government's recent 2.48% payment increase to Medicare Advantage plans has lifted insurance stock values. Neurocrine Biosciences' $2.9 billion acquisition of Soleno Therapeutics signifies its move into metabolic diseases. Weight-loss medication demand rises as patients seek cost-effective options from Novo Nordisk and Eli Lilly.
